Literature DB >> 31579558

Examining the role of precision medicine with oral baclofen in pediatric patients with cerebral palsy.

Matthew J McLaughlin1, Susan Abdel-Rahman1, J Steven Leeder1.   

Abstract

PURPOSE OF REVIEW: a)Despite its widespread use, oral baclofen requires a critical review of the pharmacology to determine potential precision medicine applications to improve medication administration. Discussing the dose→exposure→response relationship of oral baclofen allows a conceptual framework in which designing clinical trials would become more successful. This paper seeks to examine some of the areas where variability in exposures can exist lead to undesired clinical responses. RECENT
FINDINGS: b)Several factors are at play to implement precision medicine with oral baclofen in the pediatric patient with cerebral palsy. Variations in intestinal absorption, oral baclofen clearance, pharmacogenomic variants, and distribution of this medication into the cerebrospinal fluid cause differences in the amount of baclofen available at the GABA-B receptor site to cause a clinical response.
SUMMARY: c)Oral baclofen has significant variability in disposition and clinical response. Research to determine the causes for this variability and controlling for these factors would allow improvement in clinical outcomes.

Entities:  

Keywords:  baclofen; cerebral palsy; pediatrics; pharmacogenetics; precision medicine; rehabilitation

Year:  2019        PMID: 31579558      PMCID: PMC6774387     

Source DB:  PubMed          Journal:  Curr Phys Med Rehabil Rep        ISSN: 2167-4833


  17 in total

1.  Chemistry and pharmacology of GABAB receptor ligands.

Authors:  Wolfgang Froestl
Journal:  Adv Pharmacol       Date:  2010

2.  Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis.

Authors:  Y Deguchi; K Inabe; K Tomiyasu; K Nozawa; S Yamada; R Kimura
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

3.  Quality of life: effect of reduced spasticity from intrathecal baclofen.

Authors:  J M Gianino; M M York; J A Paice; S Shott
Journal:  J Neurosci Nurs       Date:  1998-02       Impact factor: 1.230

4.  The chemistry and kinetics of Lioresal.

Authors:  J W Faigle; H Keberle
Journal:  Postgrad Med J       Date:  1972-10       Impact factor: 2.401

Review 5.  Assessment and treatment of movement disorders in children with cerebral palsy.

Authors:  Laura L Deon; Deborah Gaebler-Spira
Journal:  Orthop Clin North Am       Date:  2010-10       Impact factor: 2.472

6.  Gastrointestinal manifestations in children with cerebral palsy.

Authors:  E Del Giudice; A Staiano; G Capano; A Romano; L Florimonte; E Miele; C Ciarla; A Campanozzi; A F Crisanti
Journal:  Brain Dev       Date:  1999-07       Impact factor: 1.961

7.  Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy.

Authors:  Matthew J McLaughlin; Yang He; Janice Brunstrom-Hernandez; Liu Lin Thio; Bruce C Carleton; Colin J D Ross; Andrea Gaedigk; Andrew Lewandowski; Hongying Dai; William J Jusko; J Steven Leeder
Journal:  PM R       Date:  2017-09-01       Impact factor: 2.298

8.  A controlled trial of baclofen in children with cerebral palsy.

Authors:  P J Milla; A D Jackson
Journal:  J Int Med Res       Date:  1977       Impact factor: 1.671

9.  A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state.

Authors:  M K Shellenberger; L Groves; J Shah; G D Novack
Journal:  Drug Metab Dispos       Date:  1999-02       Impact factor: 3.922

10.  Plasma and urinary excretion kinetics of oral baclofen in healthy subjects.

Authors:  E W Wuis; M J Dirks; E F Termond; T B Vree; E Van der Kleijn
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.